List view / Grid view

Nikki Withers (Drug Target Review)

Filter the results

 

article

Novel biomarker technology for cancer diagnostics

11 September 2020 | By

A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.

article

Defusing antibody neutralisers in AAV gene therapy

10 September 2020 | By

Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…

article

Petabytes of data – how informatics is transforming precision medicine

26 March 2020 | By

Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…

article

TCR therapy – an attractive alternative to CAR T

24 March 2020 | By

Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…

article

Antibody characterisation – an essential researchers’ resource

13 December 2019 | By

Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke…